§ 866.3310. Hepatitis A virus (HAV) serological assays.
153 words·~1 min read·
/us/cfr/t21/s§ 866.3310·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
(a)Identification. HAV serological assays are devices that consist of antigens and antisera for the detection of hepatitis A virus-specific IgM, IgG, or total antibodies (IgM and IgG), in human serum or plasma. These devices are used for testing specimens from individuals who have signs and symptoms consistent with acute hepatitis to determine if an individual has been previously infected with HAV, or as an aid to identify HAV-susceptible individuals. The detection of these antibodies aids in the clinical laboratory diagnosis of an acute or past infection by HAV in conjunction with other clinical laboratory findings. These devices are not intended for screening blood or solid or soft tissue donors.
(b)Classification. Class II (special controls). The special control is “Guidance for Industry and FDA Staff: Class II Special Controls Guidance Document: Hepatitis A Virus Serological Assays.” See § 866.1(e) for the availability of this guidance document. [71 FR 6679, Feb. 9, 2006]
Connections1 cite this
Cited by 1 section
Citation graph
cites case law
§ 866.3310
Hepatitis A virus (HAV) serological assays.
Fed. Reg.×1
Cites 0Cited by 1 across 1 source